FTC Narrowly Okays AbbVie/Allergan Merger As Dissenter Slams Divestitures To AstraZeneca, Nestlé

 
• By Brenda Sandburg

Commissioner Chopra says candy maker Nestlé cannot take Allergan’s place in the market and AstraZeneca would get a windfall without paying anything for a valuable drug development project. AbbVie/Allergan must divest enzyme replacement therapies Zenpap and Viokace to Nestlé and investigational IL-23 inhibitor brazikumab to AstraZeneca. 

Close-up Of King Chess Pieces On Wooden Blocks With Mergers And Acquisitions
FTC Commissioners disagree on adequacy of AbbVie/Allergan divestitures

More from Compliance

More from Pink Sheet